Ken Griffin Maia Biotechnology, Inc. Transaction History

Citadel Advisors LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.1 - $2.55 $37,096 - $85,996	-33,724 Reduced 58.68%	23,749 $52,000
Q4 2023 Feb 14, 2024	BUY	$0.83 - $2.54 $47,702 - $145,981	57,473 New	57,473 $67,000
Q2 2023 Aug 14, 2023	BUY	$2.11 - $3.84 $49,346 - $89,806	23,387 New	23,387 $51,000

1.47M

Ticker MAIA
Exchange
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,935,900
Market Cap $22.6M
Description
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company wa...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.